0001564590-21-006376.txt : 20210217 0001564590-21-006376.hdr.sgml : 20210217 20210217161204 ACCESSION NUMBER: 0001564590-21-006376 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210217 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210217 DATE AS OF CHANGE: 20210217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 21644853 BUSINESS ADDRESS: STREET 1: 12340 EL CAMINO REAL, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 12340 EL CAMINO REAL, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 vktx-8k_20210217.htm 8-K vktx-8k_20210217.htm
false 0001607678 0001607678 2021-02-17 2021-02-17 0001607678 us-gaap:CommonStockMember 2021-02-17 2021-02-17 0001607678 us-gaap:WarrantMember 2021-02-17 2021-02-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):  February 17, 2021

 

Viking Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

001-37355

 

46-1073877

(State or Other Jurisdiction of

Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

12340 El Camino Real, Suite 250, San Diego, California 92130

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (858) 704-4660

 

N/A

(Former Name, or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act

 

 

Title of Each Class

 

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.00001 per share

 

VKTX

The Nasdaq Stock Market LLC

 

Warrants to purchase Common Stock, par value $0.00001 per share

 

VKTXW

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933

(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

In this report, “Viking Therapeutics,” “Viking,” “Company,” “we,” “us” and “our” refer to Viking Therapeutics, Inc.

 

Item 2.02 Results of Operations and Financial Condition.

On February 17, 2021, we issued a press release reporting our financial results for the fourth quarter and year ended December 31, 2020 and providing a corporate update.  The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No

 

Description

99.1

 

 

Press release issued February 17, 2021, reporting financial results for the fourth quarter and year ended December 31, 2020 and providing a corporate update. 

104

 

Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

 

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Viking Therapeutics, Inc.

 

 

 

Date: February 17, 2021

By:

/s/ Brian Lian, Ph.D.

 

 

Brian Lian, Ph.D.

 

 

President and Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

 EX-99.1 2 vktx-ex991_31.htm EX-99.1 vktx-ex991_31.htm

 

Exhibit 99.1

 

 

Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

 

Conference call scheduled for 4:30 p.m. ET today

 

 

•

Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Continues to Enroll

 

•

Phase 1 Trial Evaluating VK0214 Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-2021

 

•

Balance Sheet Remains Strong; Year-End Cash Approximately $250 Million

 

 

SAN DIEGO, February 17, 2021 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2020, and provided an update on its clinical pipeline and other corporate developments.

 

Highlights from the Quarter and Year Ended December 31, 2020:

 

“2020 was a strong and productive year for Viking,” stated Brian Lian, Ph.D., chief executive officer of Viking.  “Despite the challenges posed by the global pandemic, we continued to open clinical sites and proceed with enrollment in our 52-week Phase 2b VOYAGE trial evaluating VK2809 in patients with NASH and fibrosis.  Importantly, in the face of a COVID-19 resurgence in recent months, the majority of our U.S. sites remain open, and we continue to add both U.S. and ex-U.S. sites.  We currently expect to complete enrollment in the second half of 2021.  With respect to our VK0214 program for X-linked adrenoleukodystrophy, we made excellent progress in 2020 and were pleased to announce last fall the initiation of a first-in-human study with this important molecule.  Pending successful completion of the Phase 1 single ascending and multiple ascending dose study, we plan to initiate a Phase 1b trial in X-ALD patients.  On the personnel side, we recently announced the appointment of Marianne Mancini to the position of COO and Greg Zante to CFO.  Both Marianne and Greg have exhibited strong leadership in the management of Viking’s clinical operations and financial strategy, respectively, and we are pleased to appoint them to these roles within the organization.”

 

 

Pipeline and Corporate Highlights

 

 

•

Phase 2b VOYAGE study evaluating VK2809 in biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis continues to enroll; new sites opened in the U.S. and Europe. VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH.  The company’s ongoing Phase 2b VOYAGE trial is a randomized, double-blind, placebo-controlled, multicenter study designed to assess the efficacy, safety and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis ranging from stages F1 to F3.  The study is targeting enrollment of approximately 340 patients across five treatment arms: 1.0 mg daily; 2.5 mg daily; 5.0 mg every other day; 10.0 mg every other day; and placebo.  The primary endpoint of the study will evaluate the relative change in liver fat content, as assessed by magnetic resonance imaging, proton density fat fraction (MRI-PDFF) from baseline to Week 12 in subjects treated with VK2809, as compared to placebo.  Secondary objectives include evaluation of histologic changes assessed by hepatic biopsy after 52 weeks of dosing.

 

During the fourth quarter of 2020, the company continued to enroll at our U.S. sites, and opened new clinical sites outside the U.S.  The resurgence of the pandemic in recent months continues to impact enrollment projections.  As a result, the company now expects to complete enrollment of this trial in the second half of 2021.

 

•

New data from prior VK2809 Phase 2 trial highlighted in EASL podium presentation.  In the third quarter of 2020, new data from the company’s prior 12-week Phase 2 study evaluating VK2809 in patients with non-alcoholic fatty liver disease and hypercholesterolemia were highlighted in a podium presentation at the annual meeting of the International Liver Conference (EASL).  These data demonstrated that patients treated with VK2809 continued to experience durable, statistically significant reductions in liver fat content at Week 16, four weeks after completion of dosing in the 12-week study.  The results showed that among VK2809-treated patients, the median reduction in liver fat content was maintained at 45.4% at Week 16, compared to an 18.7% reduction for placebo (p=0.0053).  Additionally, at Week 16, 70.4% of all VK2809-treated patients maintained a response, defined as experiencing ≥ 30% relative reduction from baseline in liver fat content (p=0.0083).  Of note, 100% of patients receiving 5 mg daily doses of VK2809 demonstrated a response at Week 16.  

 

The presentation also highlighted additional Week 12 results that demonstrated significant reductions in liver fat content among patients receiving VK2809 as compared to placebo regardless of the presence of common risk factors for NASH, including baseline levels of alanine aminotransferase (ALT) above the upper limit of normal (ALT > xULN), body mass index (BMI) ≥ 30, hypertension and Hispanic ethnicity.  

 

The overall results from this study, including these durability data, as well as the observed consistent efficacy across high risk subgroups, provide strong rationale for further development of VK2809 in the setting of NASH.

 

 

 

•

Phase 1 SAD/MAD Study of VK0214 Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients in Mid-2021.  VK0214 is a novel, orally available thyroid hormone receptor beta agonist being evaluated as a potential treatment for X-linked adrenoleukodystrophy (X-ALD), a devastating disease for which there is currently no therapeutic treatment.  To date, findings from in vitro and in vivo studies have demonstrated that administration of VK0214 results in a significant reduction of very long chain fatty acids in both plasma and tissue, key biomarkers of disease, suggesting a potential therapeutic benefit.   

 

In the third quarter of 2020, the company initiated a Phase 1 first-in-human trial of VK0214.  The Phase 1 trial is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy subjects. The primary objectives of the study include evaluation of the safety, tolerability, and pharmacokinetics of single and multiple oral doses of VK0214, as well as the identification of VK0214 doses for potential clinical development in the setting of X-ALD.  The company expects to complete the SAD/MAD study in the first half of 2021.  Pending evaluation of the results, Viking plans to initiate a Phase 1b proof-of-concept trial in patients with X-ALD.

 

•

Key appointments to senior management team.  Viking recently announced the appointments of Marianne Mancini as the company’s chief operating officer, and Greg Zante as chief financial officer.  Over the years, Ms. Mancini and Mr. Zante have exhibited strong leadership in clinical operations and financial strategy, respectively.  

 

Prior to her appointment as COO, Ms. Mancini served as Viking’s senior vice president of clinical operations.  She has more than 30 years of experience in the pharmaceutical and biotech industry, and has overseen the clinical advancement of the company’s VK2809, VK0214, and VK5211 programs.  As COO, Ms. Mancini is responsible for key clinical and regulatory activities related to our pipeline programs.

 

Mr. Zante has nearly 25 years of financial management experience at public and private companies in the biotechnology and accounting industries, and most recently served as Viking's senior vice president of finance.  Mr. Zante’s contributions to the company’s financial strength and stability have well-positioned Viking to achieve important clinical milestones with both lead candidates.  As CFO, Greg plays an important role in the management of the company’s financial, business development and investor relations activities.

 

 

•

Balance sheet remains strong with approximately $250 million in cash.  Viking completed the fourth quarter of 2020 with $248.4 million in cash, cash equivalents and short-term investments.  

 

 

•

Upcoming investor events.  Viking management will participate in the following upcoming investor events, all of which will be virtual: 

 

10th Annual SVB Leerink Global Healthcare Conference
Dates: February 24 - 26, 2021

 

Raymond James 2021 Institutional Investors Conference
Dates: March 1 - 3, 2021

 

H.C. Wainwright Global Life Sciences Conference

Dates: March 9 – 10, 2021

 

33rd Annual Roth Conference

Dates: March 15 – 17, 2021

 

Oppenheimer’s 31st Annual Healthcare Conference

Dates: March 16 – 17, 2021

 

20th Annual Needham Healthcare Conference

Dates: April 12 – 15, 2021

 

 

Fourth Quarter and Full-Year 2020 Financial Highlights

 

Fourth Quarter Ended December 31, 2020 and 2019

 

Research and development expenses for the three months ended December 31, 2020 were $9.0 million compared to $6.5 million for the same period in 2019.  The increase was primarily due to increased expenses related to clinical studies, salaries and benefits and stock-based compensation, partially offset by decreased expenses related to manufacturing for the company’s drug candidates and services provided by third-party consultants.

 

General and administrative expenses for the three months ended December 31, 2020 were $2.2 million compared to $2.4 million for the same period in 2019.  The decrease was primarily due to decreased expenses related to legal and patent services, professional fees and salaries and benefits, partially offset by increased expenses related to insurance.

 

For the three months ended December 31, 2020, Viking reported a net loss of $10.9 million, or $0.15 per share, compared to a net loss of $7.5 million, or $0.10 per share, in the corresponding period in 2019.  The increase in net loss and net loss per share for the three months ended December 31, 2020 was primarily due to the increase in research and development expenses, partially offset by a decrease in general and administrative expenses, as noted previously, as well as decreased interest income primarily due to the decline in interest rates available throughout the fourth quarter of 2020 as compared to prevailing interest rates during the fourth quarter of 2019.

 

 

Twelve Months Ended December 31, 2020 and 2019

 

Research and development expenses for the twelve months ended December 31, 2020 were $31.9 million compared to $23.6 million for the same period in 2019.  The increase was primarily due to increased expenses related to clinical studies, salaries and benefits, stock-based compensation and manufacturing for the company’s drug candidates, partially offset by decreased expenses related to services provided by third-party consultants, pre-clinical studies and travel.

 

General and administrative expenses for the twelve months ended December 31, 2020 were $10.7 million compared to $9.1 million for the same period in 2019.  The increase

 

was primarily due to increased expenses related to stock-based compensation, salaries and benefits and insurance, partially offset by decreased expenses related to services provided by third-party consultants, professional fees, legal and patent expenses, and travel.

 

For the twelve months ended December 31, 2020, Viking reported a net loss of $39.5 million, or $0.54 per share, compared to a net loss of $25.8 million, or $0.36 per share, in the corresponding period in 2019.  The increase in net loss and net loss per share for the twelve months ended December 31, 2020 was primarily due to the increases in research and development and general and administrative expenses noted previously, as well as decreased interest income primarily due to the decline in interest rates throughout the twelve months ended December 31, 2020 as compared to prevailing interest rates during same period in 2019.

 

 

Balance Sheet as of December 31, 2020

 

At December 31, 2020, Viking held cash, cash equivalents and short-term investments of $248.4 million, compared to $275.6 million as of December 31, 2019.

 

 

Conference Call

 

Management will host a conference call to discuss the company’s fourth quarter and year-end 2020 financial results today at 4:30 pm Eastern.  To participate in the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S.  In addition, following the completion of the call, a telephone replay will be accessible until February 24, 2021 by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering conference ID #10150687.  Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking’s website at http://ir.vikingtherapeutics.com/webcasts.  An archive of the webcast will also be available on the Webcasts page of the company’s website for 30 days.

 

 

About Viking Therapeutics, Inc. 

 

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.  Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.  In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.  The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial.  The company holds exclusive worldwide rights to a portfolio of

 

five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

 

Forward-Looking Statements

 

This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones, including the company’s expected timing for the potential initiation and completion of clinical studies in X-ALD for VK0214 and plans for completion of the company’s VOYAGE Phase 2b study, as well as the company's goals and plans regarding VK0214, VK2809 and their respective prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2809 and VK0214; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; risks related to the COVID-19 pandemic; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission, including Viking's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof.  Viking disclaims any obligation to update these forward-looking statements except as required by law.


 

Viking Therapeutics, Inc.

Statements of Operations and Comprehensive Loss

 

(In thousands, except per share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

Three Months Ended December 31,

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenues

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

9,048

 

 

 

6,451

 

 

 

31,931

 

 

 

23,559

 

General and administrative

 

 

2,217

 

 

 

2,422

 

 

 

10,731

 

 

 

9,128

 

Total operating expenses

 

 

11,265

 

 

 

8,873

 

 

 

42,662

 

 

 

32,687

 

Loss from operations

 

 

(11,265

)

 

 

(8,873

)

 

 

(42,662

)

 

 

(32,687

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of financing costs

 

 

(21

)

 

 

(46

)

 

 

(106

)

 

 

(146

)

Interest income, net

 

 

313

 

 

 

1,469

 

 

 

3,233

 

 

 

7,050

 

Realized gain on investments

 

 

25

 

 

 

—

 

 

 

40

 

 

 

4

 

Total other income, net

 

 

317

 

 

 

1,423

 

 

 

3,167

 

 

 

6,908

 

Net loss

 

 

(10,948

)

 

 

(7,450

)

 

 

(39,495

)

 

 

(25,779

)

Other comprehensive loss, net of tax:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on securities

 

 

(8

)

 

 

(145

)

 

 

(66

)

 

 

435

 

Comprehensive loss

 

$

(10,956

)

 

$

(7,595

)

 

$

(39,561

)

 

$

(25,344

)

Basic and diluted net loss per share

 

$

(0.15

)

 

$

(0.10

)

 

$

(0.54

)

 

$

(0.36

)

Weighted-average shares used to compute basic

   and diluted net loss per share

 

 

72,896

 

 

 

72,115

 

 

 

72,597

 

 

 

71,959

 

 

 

 

 


 

Viking Therapeutics, Inc.

Balance Sheets

 

(In thousands, except share and per share amounts)

 

 

 

 

December 31,

2020

 

 

December 31,

2019

 

 

 

 

(unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

29,117

 

 

$

8,377

 

Short-term investments – available for sale

 

 

219,269

 

 

 

267,261

 

Prepaid clinical trial and preclinical study costs

 

 

7,276

 

 

 

7,458

 

Prepaid expenses and other current assets

 

 

442

 

 

 

405

 

Total current assets

 

 

256,104

 

 

 

283,501

 

Right-of-use assets

 

 

321

 

 

 

598

 

Deferred public offering and other financing costs

 

 

48

 

 

 

128

 

Deposits

 

 

29

 

 

 

29

 

Total assets

 

$

256,502

 

 

$

284,256

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,988

 

 

$

2,431

 

Other accrued liabilities

 

 

7,811

 

 

 

4,044

 

Lease liability, current

 

 

330

 

 

 

302

 

Total current liabilities

 

 

12,129

 

 

 

6,777

 

Lease liability, net of current portion

 

 

29

 

 

 

360

 

Total long-term liabilities

 

 

29

 

 

 

360

 

Total liabilities

 

 

12,158

 

 

 

7,137

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019

 

 

—

 

 

 

—

 

Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2020 and 2019; 73,215,940 shares issued and outstanding at December 31, 2020 and 72,413,602 shares issued and outstanding at December 31, 2019

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

412,589

 

 

 

405,803

 

Accumulated deficit

 

 

(168,192

)

 

 

(128,697

)

Accumulated other comprehensive income (loss)

 

 

(54

)

 

 

12

 

Total stockholders’ equity

 

 

244,344

 

 

 

277,119

 

Total liabilities and stockholders’ equity

 

$

256,502

 

 

$

284,256

 

 

 

 


 

 

Contacts:

 

Viking Therapeutics

Michael Morneau

858-704-4660

mmorneau@vikingtherapeutics.com

 

Vida Strategic Partners

Stephanie Diaz (Investors)

415-675-7401

sdiaz@vidasp.com

 

Tim Brons (Media)

415-675-7402

tbrons@vidasp.com

 

 GRAPHIC 3 g5eh3xkyf4ip000001.jpg GRAPHIC begin 644 g5eh3xkyf4ip000001.jpg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end EX-101.SCH 4 vktx-20210217.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 5 vktx-20210217_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 vktx-20210217_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document - Document and Entity Information [Line Items] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common stock [Member] Common Stock [Member] Common stock warrants [Member] Warrant [Member] Document Document And Entity Information [Line Items] Document Document And Entity Information [Line Items] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 7 vktx-20210217_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 vktx-8k_20210217_htm.xml IDEA: XBRL DOCUMENT 0001607678 2021-02-17 2021-02-17 0001607678 us-gaap:CommonStockMember 2021-02-17 2021-02-17 0001607678 us-gaap:WarrantMember 2021-02-17 2021-02-17 false 0001607678 8-K 2021-02-17 Viking Therapeutics, Inc. DE 001-37355 46-1073877 12340 El Camino Real Suite 250 San Diego CA 92130 858 704-4660 false false false false Common Stock, par value $0.00001 per share VKTX NASDAQ Warrants to purchase Common Stock, par value $0.00001 per share VKTXW NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Feb. 17, 2021
Document Document And Entity Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 17, 2021
Entity Registrant Name Viking Therapeutics, Inc.
Entity Central Index Key 0001607678
Entity Emerging Growth Company false
Entity File Number 001-37355
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-1073877
Entity Address, Address Line One 12340 El Camino Real
Entity Address, Address Line Two Suite 250
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 858
Local Phone Number 704-4660
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common stock [Member]  
Document Document And Entity Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol VKTX
Security Exchange Name NASDAQ
Common stock warrants [Member]  
Document Document And Entity Information [Line Items]  
Title of 12(b) Security Warrants to purchase Common Stock, par value $0.00001 per share
Trading Symbol VKTXW
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 3 96 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports vktx-8k_20210217.htm vktx-20210217.xsd vktx-20210217_def.xml vktx-20210217_lab.xml vktx-20210217_pre.xml vktx-ex991_31.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vktx-8k_20210217.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "vktx-20210217_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "vktx-8k_20210217.htm" ] }, "labelLink": { "local": [ "vktx-20210217_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "vktx-20210217_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "vktx-20210217.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 2, "nsprefix": "vktx", "nsuri": "http://www.vikingtherapeutics.com/20210217", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "vktx-8k_20210217.htm", "contextRef": "C_0001607678_20210217_20210217", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "vktx-8k_20210217.htm", "contextRef": "C_0001607678_20210217_20210217", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Common stock warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "vktx_DocumentDocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document - Document and Entity Information [Line Items]", "label": "Document Document And Entity Information [Line Items]", "terseLabel": "Document Document And Entity Information [Line Items]" } } }, "localname": "DocumentDocumentAndEntityInformationLineItems", "nsuri": "http://www.vikingtherapeutics.com/20210217", "presentation": [ "http://www.vikingtherapeutics.com/20210217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001564590-21-006376-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-006376-xbrl.zip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end